



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

ABT-888 (Veliparib)

Catalog #: 27101

Lot #: 181211

Size: 10 mg


Structure:

CAS Registry #: 912444-00-9

Purity: ≥99%

Chemical Formula: C₁₃H₁₆N₄O

Molecular Weight: 244.29




Description: ABT-888 (Veliparib) is a potent inhibitor of both PARP-1 and PARP-2. In the MX-1 breast xenograft model (BRCA1 deletion and BRCA2 mutation), ABT-888 potentiated cisplatin, carboplatin, and cyclophosphamide, causing regression of established tumors, whereas with comparable doses of cytotoxic agents alone, only modest tumor inhibition was exhibited.

Appearance: White to beige powder.

Solubility: Soluble in DMSO.

Biological Activity: ABT-888 (Veliparib) is a potent inhibitor of both PARP-1 and PARP-2 by [³H]NAD⁺ with K_i of 5.2 nmol/L and 2.9 nmol/L, respectively. ABT-888 inhibited PARP-1 with IC₅₀ of 4.4 nM using BPS Bioscience PARP1 Chemiluminescent Assay Kit (Cat. #80551).



Storage/Stability: Store at or below -20°C.

Quality Control: The purity was determined by HPLC analysis.

References:

1. Donawho, C. K., et al., *Clinical Cancer Research* May 2007 13; 2728.
2. Sanchez, E. V., et al., Meeting: 2009 ASCO Annual Meeting. Citation: *J Clin Oncol*. 27: 15s, 2009 (suppl; abstr 11028).
3. Liu, SK., et al., *Radiother Oncol*. 2008 Aug; **88(2)**: 258-68.